The antiapoptotic
protein BCL2 plays critical roles in regulating lymphocyte development and immune responses, and has also been implicated in
tumorigenesis and
tumor survival. However, it is unknown whether BCL2 is critical for antitumor immune responses. We evaluated whether
venetoclax, a selective small-molecule inhibitor of BCL2, would influence the antitumor activity of
immune checkpoint inhibitors (ICI). We demonstrate in mouse syngeneic
tumor models that
venetoclax can augment the antitumor efficacy of ICIs accompanied by the increase of PD-1+ T effector memory cells.
Venetoclax did not impair human T-cell function in response to
antigen stimuli in vitro and did not antagonize T-cell activation induced by anti-PD-1. Furthermore, we demonstrate that the antiapoptotic family member BCL-XL provides a survival advantage in effector T cells following inhibition of BCL2. Taken together, these data provide evidence that
venetoclax should be further explored in combination with ICIs for
cancer therapy. SIGNIFICANCE: The antiapoptotic
oncoprotein BCL2 plays critical roles in
tumorigenesis,
tumor survival, lymphocyte development, and immune system regulation. Here we demonstrate that
venetoclax, the first FDA/European Medicines Agency-approved BCL2 inhibitor, unexpectedly can be combined preclinically with
immune checkpoint inhibitors to enhance anticancer
immunotherapy, warranting clinical evaluation of these combinations.This article is highlighted in the In This Issue feature, p. 1.